Introduction
Bronchiolitis obliterans and paraneoplastic pemphigus (PNP) are rare, ominous complications of Castleman disease [1] , and they have been reported as part of paraneoplastic autoimmune multiorgan syndrome (PAMS) [2] . Irrespective of the underlying malignancy driving PAMS, the clinical outcomes are uniformly poor because of secondary respiratory failure and no standard treatment regimen, given the clinical rarity of the syndrome. We describe 2 patients with PAMS secondary to Castleman disease. In conjunction with treatment for Castleman disease, the patients also received therapy based on a transplant protocol for bronchiolitis obliterans and standard therapy for pemphigus [3] [4] [5] (intravenous immunoglobulin [IVIg], rituximab, and rosuvastatin; and fluticasone, azithromycin, and montelukast [FAM therapy]) [3-5].
Case reports
A 39-year-old woman without a smoking history was evaluated for dyspnea on exertion. She had a history of recurrent unicentric Castleman disease complicated by PNP ( Fig. 1 ). Her initial pulmonary function tests (PFTs) in August 2017 showed a forced vital capacity (FVC) of 63% and a forced expiratory volume in the first second of expiration (FEV 1 ) of 37% (FEV 1 /FVC ratio, 59%). Computed tomography (CT) showed mild, diffuse bronchial wall thickening and multiple patchy areas of air-trapping consistent with small airway disease (Fig. 2 ). After initiation of the above treatment regimen, the patient's respiratory symptoms began to improve ( Fig. 3 ). However, shortly thereafter, she discontinued azithromycin and rosuvastatin because of muscle aches, which she said were intolerable. Repeat PFTs in December 2017 showed progressive respiratory failure (FVC, 55%; FEV 1 , 23%; FEV 1 /FVC ratio, 43%). Currently, she is undergoing extracorporeal photopheresis, which has been used to treat patients with bronchiolitis obliterans after hematopoietic stem cell transplant (HSCT).
A 40-year-old man without a smoking history was evaluated for dyspnea on exertion. He also had a history of unicentric Castleman disease complicated by PNP ( Fig. 4 ). Initial pulmonary function tests (PFTs) in November 2016 showed a forced vital capacity (FVC) of 69% and a forced expiratory volume in the first second of expiration (FEV 1 ) of 41% (FEV 1 /FVC ratio, 58%). Computed tomography (CT) showed mild, diffuse bronchial wall thickening and multiple patchy areas of airtrapping consistent with small airway disease. After initiation of the above treatment regimen, the patient's respiratory symptoms began to improve ( Fig. 5 ). He remained therapy compliant, and repeat PFTs in October 2017 showed a relatively stable condition (FVC, 88%; FEV 1 , 60%; FEV 1 /FVC ratio, 68%). On most recent follow-up in April 2018, his chest CT showed stability of his respiratory disease ( Fig. 6 ).
Discussion
Among patients with Castleman disease who succumb to PAMS, the most common cause of mortality is progressive respiratory failure due to bronchiolitis obliterans, for which there are no agreed upon therapeutic options. The mechanism for this respiratory failure, initially proposed by Nousari et al., [6] is related to the unique autoantibodies in PNP. Unlike pemphigus vulgaris, which has autoantibodies to desmogleins 1 and 3 that do not cross-react with respiratory epithelia, various autoantibodies of PNP do react (desmoplakin I, bullous pemphigoid antigen I, desmoplakin II, envoplakin, periplakin, plectin, a previously unidentified 170 kD protein, and α-2-macroglobulin-like-1) [6] [7] [8] . Rat bladder antibody testing by immunofluorescence is often used as a surrogate for antibodies to envoplakin, periplakin, and desmoplakins, although desmogleins 1 and 3 (the autoantibody targets in non-PNP) are not present [8] .
The mainstay of therapy for paraneoplastic manifestations of Castleman disease is definitive treatment of the neoplasm. However, autoimmune features can persist, especially in recurrent disease [9] . IVIg and rituximab were effective in resolving our patients' mucocutaneous lesions after surgery for Castleman disease recurrences. FAM therapy and rosuvastatin are given to patients for bronchiolitis obliterans after HSCT and for chronic lung rejection because of their antiinflammatory effects: orally inhaled fluticasone (topical anti-inflammatory effects), azithromycin (impaired interleukin-8 production), and montelukast (blockade of leukotriene production). Our first patient initially improved but then had progressive respiratory decline, which may have resulted from noncompliance to therapy or the natural course of her disease. The paraneoplastic respiratory manifestations in our second patient have all but resolved, however, as demonstrated by improvement in symptoms, PFTs, and chest imaging. Further study is needed to further characterize the context in which this treatment regimen may be most beneficial. We believe the therapy regimen we used for our patients may be valuable for treating this rare clinical condition.
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